{
    "clinical_study": {
        "@rank": "11622", 
        "arm_group": [
            {
                "arm_group_label": "Hirudoid cream", 
                "arm_group_type": "Experimental", 
                "description": "Patient treated with Hirudoid cream 0.3% Mucopolysaccharide polysulfate\nTwice daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients treated with placebo cream without active substance\nTwice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "Patients receiving nutritional emulsion for at least 3 days will be treated with Hirudoid\n      cream or placebo cream to prevent and treat phlebitis caused by the infusion. The treatment\n      is continued after the end of infusion for at least 7 days.\n\n      Number of patients developing superficial phlebitis and duration of phlebitis will be\n      recorded."
        }, 
        "brief_title": "Efficacy and Tolerability of Hirudoid Cream in Prophylaxis and Treatment Infusion Phlebitis", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Thrombophlebitis", 
            "Phlebitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Phlebitis", 
                "Thrombophlebitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who are admitted to the hospital requiring to receive infusion     of a\n             complete nutritional emulsion for  3 days (Kabiven\u00ae Peripheral, 1400 kcal, 1920 ml,\n             750 mosmol/L, pH 5.6),\n\n          -  Aged 18-65 years.\n\n          -  Patients who are able to understand the requirements of the study and agree to sign\n             an informed consent, approved by an Independent Ethic Committee (IEC)/Institutional\n             Review Board (IRB), prior to the study.\n\n        Exclusion Criteria:\n\n          -  Patients known to be allergic to Hirudoid or any ingredients of Hirudoid\n\n          -  Patients with impaired skin integrity caused by lesion or soft tissue trauma\n\n          -  Patients having skin lesions with ulcerations or any other severe dermatologic\n             disease\n\n          -  Patients has been received a complete nutritional emulsion infusion within 7 days of\n             inclusion\n\n          -  Patients with severe uncontrolled medical conditions, which makes it undesirable or\n             unsafe for the patients to participate in the study, such as: Acute or chronic\n             uncontrolled severe infections,Unstable angina pectoris, symptomatic congestive heart\n             failure, myocardial infarction, serious uncontrolled cardiac arrhythmia or any other\n             clinically serious cardiac disease, Uncontrolled diabetes as defined by fasting serum\n             glucose > 1.5 x ULN; optimal glycaemic control should be achieved before starting\n             trial therapy, Uncontrolled bleeding\n\n          -  Patients known to have coagulation disorders such as Haemophilia, Thrombocytopenia,\n             Thrombosis, Other severe hematologic conditions like leukaemia, especially with\n             abnormal coagulation\n\n          -  Patients who have symptoms of microangiopathy (small vessel disease) or neuropathy\n             related to diabetes and other diseases\n\n          -  Patients with hyperthyroidism and hypothyroidism\n\n          -  Patients who are pregnant or breast feeding\n\n          -  Patients who are on anticoagulant therapy (last 2 weeks)\n\n          -  Patients with severe psychiatric conditions\n\n          -  Patients who are unable to bear legal responsibility or unable to understand the\n             study\n\n          -  Patients who are unreliable or unable to comply with the protocol, like alcohol or\n             drug abusers\n\n          -  Patients who had been participated in another clinical trial in the past 12 weeks\n\n          -  Patient is relatives of, or staff directly reporting to, the investigator\n\n          -  Patient is employee of the sponsor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01943006", 
            "org_study_id": "Hir-901113"
        }, 
        "intervention": [
            {
                "arm_group_label": "Hirudoid cream", 
                "description": "Hirudoid cream", 
                "intervention_name": "Hirudoid cream 0.3 % Mucopolysaccharide polysulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo cream without active substance", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Mucopolysaccaride polysulfate (MPS)", 
            "MPS", 
            "Heparinoide", 
            "Infusionphlebitis", 
            "Prevention", 
            "Superficial thrombophlebitis", 
            "Treatment"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Varut Loshiriwat, MD", 
                    "phone": "+66 892 165 298"
                }, 
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "107000"
                    }, 
                    "name": "Siriraj Hospital"
                }, 
                "investigator": {
                    "last_name": "Varut Lohsiriwat, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "khulsittijinda1@yahoo.com", 
                    "last_name": "Nathapong Khulasittijinda, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand"
                    }, 
                    "name": "General Police Hospital"
                }, 
                "investigator": {
                    "last_name": "Nathapong Khulasittijinda, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Santi Lokecharoenlarb, MD", 
                    "phone": "+66 89 119 9190"
                }, 
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand"
                    }, 
                    "name": "Rajvithi Hospital"
                }, 
                "investigator": {
                    "last_name": "Santi Lokecharoenlarb, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Boonchoo Sirichindakul, MD", 
                    "phone": "+66 2 256 4117"
                }, 
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand"
                    }, 
                    "name": "Chulalongkorn Hospital"
                }, 
                "investigator": {
                    "last_name": "Boonchoo Sirichindakul, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Tolerability of Hirudoid Cream in Prophylaxis and Treatment of Superficial Infusion Thrombophlebitis", 
        "other_outcome": [
            {
                "description": "Laboratory test performed on day 1 and at the end of the study", 
                "measure": "Fasting blood glucose (FBS)", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Laboratory testing is performed on day 1 and end of study", 
                "measure": "Platelet, red blood cell and leukocyte count", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Laboratory testing is performed on day 1 and end of study", 
                "measure": "Alanine transaminase (ALT),", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Laboratory testing is performed on day 1 and end of study", 
                "measure": "Aspartate transaminase (AST),", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Laboratory testing is performed on day 1 and end of study", 
                "measure": "Fibrinogen and activated partial thromboplastin time (aPTT)", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Laboratory testing is performed on day 1 and end of study", 
                "measure": "Prothrombin time (PT)", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Laboratory testing is performed on day 1 and end of study", 
                "measure": "Serum creatinine", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }
        ], 
        "overall_contact": {
            "email": "tun.myint.win@dksh.com", 
            "last_name": "Tun Myint Win, MD", 
            "phone": "+66 8 1847 5696"
        }, 
        "overall_contact_backup": {
            "email": "grob.philipp@medinova.ch", 
            "last_name": "Philipp Grob, PhD", 
            "phone": "+41792910960"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Thailand: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of patient developing superficial thrombophlebitis", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01943006"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to develop infusion related superficial thrombophlebitis", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Pain score (10-point visual analogue score) Extent of erythema", 
                "measure": "Change of clinical symptoms in patients who developed superficial thrombophlebitis", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Time to complete resolution of signs and symptoms in patients who developed superficial thrombophlebitis", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "4-point rating scale", 
                "measure": "Investigators' satisfaction", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "4-point rating scale", 
                "measure": "Patient' satisfaction", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Number of any adverse events and adverse drug reactions including their severity experienced by the patients during the course of therapy", 
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Rating of tolerance by investigator and patients using targeted questionnaire 4-point scale (very good, good, moderate, no change or deterioration) at the end of the study", 
                "measure": "Global tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }
        ], 
        "source": "Medinova AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medinova AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}